公司财务报告问题 - 公司被指控在2020年10月7日至2024年3月19日期间对业务运营和前景做出重大虚假和误导性陈述 [2] - 公司存在财务报告内部控制缺陷 导致多次发布不准确财务报表并需要重述 [2] - 公司针对上述缺陷的补救措施无效 影响其按时向SEC提交定期报告的能力 [2] 法律调查进展 - 股东权利律师事务所Bragar Eagel & Squire正在代表长期股东调查公司董事会可能违反 fiduciary duties 的情况 [1] - 集体诉讼已于2024年7月29日提起 涉及2020年10月7日至2024年3月19日的类别期间 [1] - 公司财务状况和前景被指控存在重大高估 公开声明在相关时间均具有重大虚假性和误导性 [2] 投资者参与方式 - 长期持股投资者可通过电话(212) 355-4648或邮箱investigations@bespc.com联系Brandon Walker或Marion Passmore讨论法律权利 [3][6] - 咨询无需成本或义务 律师事务所在美国多州设有办公室 专门处理证券和复杂诉讼案件 [4][6]

Lifecore Biomedical (LFCR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended August 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the s ...

CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newl ...

PresentationDaniel Cohen Good afternoon. Thanks for joining us. I'm Daniel Cohen. I'm a Managing Director in the -- at Morgan Stanley. I do have to read a disclosure before we start. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, we will kick it off. Very honored to have my friend, Paul Josephs, CEO of Lifecore, here with ...

Lifecore Biomedical (NasdaqGS:LFCR) FY Conference September 09, 2025 04:50 PM ET Company ParticipantsDaniel Cohen - Managing DirectorPaul Josephs - CEODaniel CohenGood afternoon. Thanks for joining us. I'm Daniel Cohen. I'm a Managing Director at Morgan Stanley. I do have to read a disclosure before we start. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com. If you have any questions, please reach out to your Morgan Stanley sales representative. W ...

公司动态 - Lifecore Biomedical将作为金牌赞助商参加2025年9月18-19日在新泽西州新不伦瑞克举行的第24届Contract Pharma合同与外包会议 并在桌展35号桌进行展示[1][2] - 公司首席商务官Mark DaFonseca表示 此次活动旨在提升市场对其注射剂开发和制造专业知识的认知 并展示40年以上的合作成功经验[3] - 会议期间公司团队将与现有及潜在客户和合作伙伴举行现场会议 联系方式为info@lifecore.com或LinkedIn主页[3] 业务战略 - 参会行动基于公司三管齐下的增长战略执行 包括扩大现有客户关系 推进后期开发组合商业化 以及吸引新的高价值业务[2] - 公司强调其基于隔离器的先进灌装技术能力 认为这对寻求美国制造合作伙伴的赞助商具有吸引力[3] 公司背景 - Lifecore Biomedical是一家完全整合的合同开发与制造组织（CDMO） 专注于无菌注射药物产品的开发 灌装和完成 包括复杂配方[4] - 作为优质注射级透明质酸的领先制造商 公司拥有40多年经验 为全球及新兴生物制药和生物技术公司提供跨治疗领域的创新解决方案[4]

CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Morgan Stanley 23rd Annual Global Healthcare ConferenceDetails: Lifecore management will participate in a fireside chat and in investor meetingsConference Dates: September 8- ...

公司财务报告问题 - 公司被指控在2020年10月7日至2024年3月19日期间对财务报告维持有缺陷的内部控制 [2] - 公司因此发布了多份不准确的财务报表并需要进行重述 [2] - 公司针对上述缺陷的所谓补救措施被指控为无效 [2] 公司信息披露与合规问题 - 前述问题损害了公司及时向SEC提交符合纳斯达克上市要求的定期报告的能力 [2] - 公司的财务状况和/或前景被指控为被严重夸大 [2] - 公司的公开陈述在所有相关时间被指控为存在严重虚假和误导性 [2] 法律调查与投资者联系 - 律师事务所代表长期股东调查公司董事会是否违反了对公司的信托责任 [1] - 针对公司的集体诉讼已于2024年7月29日提交 [1] - 鼓励在上述期间遭受损失的长期股东直接联系讨论法律权利 [1][3]

This presentation contains non-GAAP financial information including Adjusted EBITDA. The Company has included a reconciliation of Adjusted EBITDA to net (loss) income, the most directly comparable financial measure calculated in accordance with GAAP. We define Adjusted EBITDA as net (loss) income as determined under GAAP excluding (i) interest expense, net of interest income, (ii) income tax expense (benefit), (iii) depreciation and amortization, (iv) stock-based compensation, (v) change in fair value of de ...

This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this agricultural and food packaging products company would post a loss of $0.14 per share when it actually produced a loss of $0.19, delivering a surprise of -35.71%. Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. Ove ...